Nxera
"Nxera" is a figurative mark owned by Nxera Pharma Co., Ltd., filed at the EUIPO on July 15, 2024. It is registered and covers classes 1, 5, 35, 42 and 44.
- Status
- Registered
- Since July 3, 2025
- Filed
- July 15, 2024
- Registered
- July 2, 2025
- Expires
- July 15, 2034
- Application no.
- 019054464
- Registration no.
- 019054464
- Office
- EUIPO
- European Union Intellectual Property Office
- Mark type
- Figurative mark
- 5 classes
Who owns Nxera
The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.
Owner
Nxera Pharma Co., Ltd.
Representative
Luca Colombo
What the mark covers
The products and services Nxera is filed for, grouped by Nice class.
Chemical products and proteins for manufacturing chemical and biological pharmaceutical products; chemical products and proteins for the research of chemical and biological pharmaceutical products; chemical products and proteins for diagnostic use, except medical or veterinary uses; proteins and Gprotein- coupled receptors for manufacturing pharmaceutical products; proteins and G-protein -coupled receptors for the research of pharmaceutical products; chemicals and proteins for chemical and biological drug discovery, lead identification and diagnostics; proteins and Gprotein- coupled receptors for drug discovery purposes; chemicals and biologicals, including proteins, transmembrane proteins and G proteins, G-protein-coupled receptors, and fragments thereof being sequences of amino acids, for chemical and biological drug discovery, lead identification and diagnostics; proteins, including transmembrane proteins and G-proteins, G-protein-coupled receptors, and fragments thereof being sequences of amino acids, for use in pharmaceutical research, including, drug discovery purposes; Biological products for use in chemical and biological drug discovery, lead identification and diagnostics; Biological formulation for developing chemical and biological pharmaceutical products; Biological formulation for identifying lead chemical and biological products; Proteins and G-protein-coupled receptors for drug discovery purposes; Gprotein- coupled receptors, transmembrane proteins and parts thereof for use in chemical and biological drug discovery and lead identification
Pharmaceutical preparations; medicines; biological products for medical purposes, namely, G-proteincoupled receptors, transmembrane proteins and parts thereof for diagnostics and therapeutic purposes; biological and chemical products for medical use, namely, proteins, G-proteincoupled receptors, modulators of G-protein coupled receptors, transmembrane proteins, G-proteins, antibodies and peptides and parts thereof, for therapeutic purposes; chemicals, proteins and parts thereof for use in medical diagnostics; biological products for therapeutic purposes: biological formulation for diagnostic use; biological formulation for therapeutic use; proteins and G-proteincoupled receptors for drug discovery purposes; biologicals and small chemical entities, including proteins, G-protein-coupled receptors, modulators of G-protein coupled receptors, transmembrane proteins, G-proteins, antibodies and peptides for therapeutic purposes; proteins, Gprotein- coupled receptors, transmembrane proteins, G-proteins, antibodies and peptides for use in medical diagnostics
Business management, organisation and administration in the field of chemical products, biological products, pharmaceuticals, design and development of drugs, drug discovery; business management, organisation and administration in the field of research and development services in the pharmaceutical and biopharmaceutical fields, including technologies related to proteins and G-protein-coupled receptors; retail and wholesale services connected with the sale of pharmaceuticals, biological products and chemical and biological preparations
Drug and pharmaceutical discovery services; bio-technology, pharmaceutical, chemical and medical testing, research, development, advice, consultancy and information services; research and development services in the pharmaceutical and biopharmaceutical fields, including technologies related to proteins and G-protein-coupled receptors; pharmaceutical research services in chemical and biological drug discovery and development; research and development services for identifying lead chemical compounds; examination and research services in medicinal and synthetic chemistry; research and development services in the creation of libraries or collections of biologicals, chemicals and compounds; research, creation, development and provision of chemical and biological drug targets for screening purposes; research, analysis and examination for identification of compounds through automated screening processes; research and development services in chemical and biological pharmaceutical development; medical research laboratory services; provision of information, advisory services and consultancy relating to the aforesaid services
Pharmaceutical services; pharmaceutical advice and consultancy for medical purposes; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; all of the aforesaid relating to drug discovery and use of Gprotein- coupled receptors in the design and development of pharmaceutical products
What has happened so far
Steps recorded by the EUIPO, newest first.
- Bulletin 2025/123 Section C.2.1
- Bulletin 2025/121 Section B.1
- Bulletin 2025/056 Section A.1
About Nxera
Who owns the trademark "Nxera"?
The EUIPO trademark "Nxera" (application 019054464) is owned by Nxera Pharma Co., Ltd.
What is the status of "Nxera"?
Its status at the EUIPO is: registered.
When was "Nxera" registered?
It was registered on July 2, 2025 and is due to expire on July 15, 2034.
Get this data via the API
Everything on this page comes from the Signa API. Pull Nxera and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_019d4702-19e5-766d-9a6b-8eaff09be1b0
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_019d4702-19e5-766d-9a6b-8eaff09be1b0",
"object": "trademark",
"mark_text": "Nxera",
"status": {
"primary": "active",
"stage": "registered"
},
"office_code": "EM",
"application_number": "019054464",
"filing_date": "2024-07-15",
"nice_classes": [
1,
5,
35,
42,
44
],
"owners": [
{
"name": "Nxera Pharma Co., Ltd.",
"entity_id": "ent_019ebaba-1670-77fd-a8ef-7433192214fd"
}
]
}